Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dyax down on DX-88 BLA plans

DYAX was down $1.99 (25%) to $6.08 on 2.4 million shares on Friday

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE